A South Korean biotech company is likely to benefit greatly from the policy of the U.S. Food and Drug Administration, which ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech ...

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.

Krystal Biotech KRYS reported first-quarter 2025 earnings ... is currently developing a décolleté-specific photo numeric scale for advanced clinical development of KB301. This subsidiary expects ...

Krystal Biotech KRYS reported first-quarter 2025 earnings per share (EPS) of $1.20, which missed the Zacks Consensus Estimate ...

Thank you for standing by, and welcome to the Krystal Biotech First Quarter 2025 Earnings Call. At this time, all participants are on a listen-only mode. After the speakers' presentations, there will ...

To this end, CRISPR Therapeutics is currently managing five other clinical trials, with several more pre-clinical studies ...

PITTSBURGH, May 06, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company”) (NASDAQ: KRYS) today reported financial results for the first quarter ending March 31, 2025 and provided a business ...

The company, best known for its multiple sclerosis (MS) drug Briumvi, posted its first-quarter results that morning, and ...

Q1 2025 Earnings Call Transcript May 8, 2025 Operator: Good afternoon, and welcome to OmniAb, Inc. First quarter 2025 financial results and business update conference call. At this time, all ...

PITTSBURGH, May 06, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS ... is currently developing a décolleté-specific photo numeric scale for advanced clinical development of KB301.

Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors</p ...